{"formats":[{"name":"JSON","format":"json","url":"\/downloads\/2025\/code-json\/54.1-3450.json"},{"name":"Plain Text","format":"text","url":"\/downloads\/2025\/code-text\/54.1-3450.txt"},{"name":"XML","format":"xml","url":"\/downloads\/2025\/code-xml\/54.1-3450.xml"},{"name":"HTML","format":"html","url":"\/downloads\/2025\/code-html\/54.1-3450.html"}],"law_id":76280,"edition_id":1,"section_id":76280,"structure_id":13782,"section_number":"54.1-3450","catch_line":"Schedule III","history":"1972, c. 798, \u00a7 54-524.84:8; 1976, c. 614; 1977, c. 302; 1979, c. 387; 1982, c. 505; 1988, cc. 283, 765; 1992, c. 737; 2000, cc. 135, 348; 2003, c. 640; 2005, c. 119; 2006, c. 346; 2007, c. 14; 2010, c. 423; 2013, c. 233; 2014, c. 74; 2015, c. 303.","full_text":"The controlled substances listed in this section are included in Schedule III:\n\n1\n\nUnless specifically exempted or listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:\n\t\t\tAny substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules;\n\t\t\tAny compound, mixture or preparation containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and one or more other active medicinal ingredients which are not listed in Schedules II through V;\n\t\t\tAny suppository dosage form containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and approved by the Food and Drug Administration for marketing only as a suppository;\n\t\t\tChlorhexadol;\n\t\t\tAny drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355);\n\t\t\tEmbutramide;\n\t\t\tKetamine, its salts, isomers, and salts of isomers (some other names: [+-] -2-[2-chlorophenyl]-2-[methylamino]-cyclohexanone);\n\t\t\tLysergic acid;\n\t\t\tLysergic acid amide;\n\t\t\tMethyprylon;\n\t\t\tPerampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benxonitrile], including its salts, isomers, and salts of isomers;\n\t\t\tSulfondiethylmethane;\n\t\t\tSulfonethylmethane;\n\t\t\tSulfonmethane; and\n\t\t\tTiletamine-zolazepam combination product or any salt thereof.2\n\nNalorphine.3\n\nUnless specifically excepted or unless listed in another schedule:\n\t\t\ta. Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts thereof:\n\t\t\tBuprenorphine.\n\t\t\tb. Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:\n\t\t\tNot more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;\n\t\t\tNot more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.4\n\nUnless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:\n\t\t\tBenzphetamine;\n\t\t\tChlorphentermine;\n\t\t\tClortermine;\n\t\t\tPhendimetrazine.5\n\nThe Board may except by regulation any compound, mixture, or preparation containing any stimulation or depressant substance listed in subsection A from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.6\n\nUnless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation:\n\t\t\tAnabolic steroids, including, but not limited to:\n\t\t\t3beta,17-dihydroxy-5a-androstane;\n\t\t\t3alpha,17beta-dihydroxy-5a-androstane;\n\t\t\t5alpha-androstan-3,17-dione;\n\t\t\t1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene);\n\t\t\t1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);\n\t\t\t4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);\n\t\t\t5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);\n\t\t\t1-androstenedione ([5alpha]-androst-1-en-3,17-dione);\n\t\t\t4-androstenedione (androst-4-en-3,17-dione);\n\t\t\t5-androstenedione (androst-5-en-3,17-dione);\n\t\t\tBolasterone (7alpha,17alpha-dimenthyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tBoldenone (Dehydrotestosterone)(17beta-hydroxyandrost-1,4,-diene-3-one);\n\t\t\tBoldione (androsta-1, 4-diene-3, 17-dione);\n\t\t\tCalusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tClostebol (4-Chlorotestosterone)(Chlorotestosterone)(4-chloro-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tDehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);\n\t\t\tDelta1-dihydrotestosterone (1-testosterone)(17beta-hydroxy-5alpha-androst-1-en-3-one);\n\t\t\tDesoxymethyltestosterone (madol)(17alpha-methyl-5alpha-androst-2-en-17beta-ol);\n\t\t\tDromostanolone (Drostanolone)(17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);\n\t\t\tEthylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);\n\t\t\tFluoxymesterone (9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one);\n\t\t\tFormyldienolone (Formebolone)(2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-di en-3-one);\n\t\t\tFurazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);\n\t\t\t13-beta-ethyl-17alpha-hydroxygon-4-en-3-one;\n\t\t\t4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);\n\t\t\t4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);\n\t\t\tMestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);\n\t\t\tMesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);\n\t\t\tMethandriol (methylandrostenediol)(17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);\n\t\t\tMethandrostenolone (Methandienone)(Dehydromethyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);\n\t\t\tMethasterone (2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one);\n\t\t\tMethenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);\n\t\t\t17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane;\n\t\t\t17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;\n\t\t\t17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene);\n\t\t\t17alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);\n\t\t\tMethyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);\n\t\t\tMethyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);\n\t\t\t17-Methyltestosterone (Methyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tMibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\t17alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)(17-alpha-methyl-1-testosterone);\n\t\t\tNandrolone (19-Nortestosterone)(17beta-hydroxyestr-4-en-3-one);\n\t\t\t19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);\n\t\t\t19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene);\n\t\t\t19-nor-4-androstenediol (3alpha,17beta-dihydroxyestr-4-ene);\n\t\t\t19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene);\n\t\t\t19-nor-5-androstenediol (3alpha,17beta-dihydroxyestr-5-ene);\n\t\t\t19-nor-4-androstenedione (estr-4-en-3,17-dione);\n\t\t\t19-nor-5-androstenedione (estr-5-en-3,17-dione);\n\t\t\tNorbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);\n\t\t\tNorclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);\n\t\t\tNorethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\tNormethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\tOxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);\n\t\t\tOxymesterone (Oxymestrone)(17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);\n\t\t\tOxymetholone (Anasterone)(17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-androstan-3-one);\n\t\t\tProstanozol (17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole);\n\t\t\tStanolone (4-Dihydrotestosterone)(Dihydrotestosterone)(17beta-hydroxy-androstan-3-one);\n\t\t\tStanozolol (Androstanazole)(17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-pyrazole);\n\t\t\tStenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);\n\t\t\tTestolactone (1-Dehydrotestololactone)(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);\n\t\t\tTestosterone (17beta-hydroxandrost-4-en-3-one);\n\t\t\tTetrahydrogestrinone (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);\n\t\t\tTrenbolone (Trienbolone)(Trienolone)(17beta-hydroxyestr-4,9,11-trien-3-one); and\n\t\t\tAny salt, ester, or ether of a drug or substance described or listed in this paragraph. However, such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the United States Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes any such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subsection.7\n\nDronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration.","order_by":null,"text":{"0":{"id":273838,"text":"The controlled substances listed in this section are included in Schedule III:","type":"section","prefixes":[""],"prefix":"","entire_prefix":"","prefix_anchor":"","level":1,"next_prefix":"1"},"1":{"id":273839,"text":"Unless specifically exempted or listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:\n\t\t\tAny substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules;\n\t\t\tAny compound, mixture or preparation containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and one or more other active medicinal ingredients which are not listed in Schedules II through V;\n\t\t\tAny suppository dosage form containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and approved by the Food and Drug Administration for marketing only as a suppository;\n\t\t\tChlorhexadol;\n\t\t\tAny drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355);\n\t\t\tEmbutramide;\n\t\t\tKetamine, its salts, isomers, and salts of isomers (some other names: [+-] -2-[2-chlorophenyl]-2-[methylamino]-cyclohexanone);\n\t\t\tLysergic acid;\n\t\t\tLysergic acid amide;\n\t\t\tMethyprylon;\n\t\t\tPerampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benxonitrile], including its salts, isomers, and salts of isomers;\n\t\t\tSulfondiethylmethane;\n\t\t\tSulfonethylmethane;\n\t\t\tSulfonmethane; and\n\t\t\tTiletamine-zolazepam combination product or any salt thereof.","type":"section","prefixes":["1"],"prefix":"1","entire_prefix":"1","prefix_anchor":"1","level":1,"prior_prefix":"","next_prefix":"2"},"2":{"id":273840,"text":"Nalorphine.","type":"section","prefixes":["2"],"prefix":"2","entire_prefix":"2","prefix_anchor":"2","level":1,"prior_prefix":"1","next_prefix":"3"},"3":{"id":273841,"text":"Unless specifically excepted or unless listed in another schedule:\n\t\t\ta. Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts thereof:\n\t\t\tBuprenorphine.\n\t\t\tb. Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:\n\t\t\tNot more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;\n\t\t\tNot more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.","type":"section","prefixes":["3"],"prefix":"3","entire_prefix":"3","prefix_anchor":"3","level":1,"prior_prefix":"2","next_prefix":"4"},"4":{"id":273842,"text":"Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:\n\t\t\tBenzphetamine;\n\t\t\tChlorphentermine;\n\t\t\tClortermine;\n\t\t\tPhendimetrazine.","type":"section","prefixes":["4"],"prefix":"4","entire_prefix":"4","prefix_anchor":"4","level":1,"prior_prefix":"3","next_prefix":"5"},"5":{"id":273843,"text":"The Board may except by regulation any compound, mixture, or preparation containing any stimulation or depressant substance listed in subsection A from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.","type":"section","prefixes":["5"],"prefix":"5","entire_prefix":"5","prefix_anchor":"5","level":1,"prior_prefix":"4","next_prefix":"6"},"6":{"id":273844,"text":"Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation:\n\t\t\tAnabolic steroids, including, but not limited to:\n\t\t\t3beta,17-dihydroxy-5a-androstane;\n\t\t\t3alpha,17beta-dihydroxy-5a-androstane;\n\t\t\t5alpha-androstan-3,17-dione;\n\t\t\t1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene);\n\t\t\t1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);\n\t\t\t4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);\n\t\t\t5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);\n\t\t\t1-androstenedione ([5alpha]-androst-1-en-3,17-dione);\n\t\t\t4-androstenedione (androst-4-en-3,17-dione);\n\t\t\t5-androstenedione (androst-5-en-3,17-dione);\n\t\t\tBolasterone (7alpha,17alpha-dimenthyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tBoldenone (Dehydrotestosterone)(17beta-hydroxyandrost-1,4,-diene-3-one);\n\t\t\tBoldione (androsta-1, 4-diene-3, 17-dione);\n\t\t\tCalusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tClostebol (4-Chlorotestosterone)(Chlorotestosterone)(4-chloro-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tDehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);\n\t\t\tDelta1-dihydrotestosterone (1-testosterone)(17beta-hydroxy-5alpha-androst-1-en-3-one);\n\t\t\tDesoxymethyltestosterone (madol)(17alpha-methyl-5alpha-androst-2-en-17beta-ol);\n\t\t\tDromostanolone (Drostanolone)(17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);\n\t\t\tEthylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);\n\t\t\tFluoxymesterone (9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one);\n\t\t\tFormyldienolone (Formebolone)(2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-di en-3-one);\n\t\t\tFurazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);\n\t\t\t13-beta-ethyl-17alpha-hydroxygon-4-en-3-one;\n\t\t\t4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);\n\t\t\t4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);\n\t\t\tMestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);\n\t\t\tMesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);\n\t\t\tMethandriol (methylandrostenediol)(17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);\n\t\t\tMethandrostenolone (Methandienone)(Dehydromethyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);\n\t\t\tMethasterone (2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one);\n\t\t\tMethenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);\n\t\t\t17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane;\n\t\t\t17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;\n\t\t\t17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene);\n\t\t\t17alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);\n\t\t\tMethyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);\n\t\t\tMethyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);\n\t\t\t17-Methyltestosterone (Methyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tMibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\t17alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)(17-alpha-methyl-1-testosterone);\n\t\t\tNandrolone (19-Nortestosterone)(17beta-hydroxyestr-4-en-3-one);\n\t\t\t19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);\n\t\t\t19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene);\n\t\t\t19-nor-4-androstenediol (3alpha,17beta-dihydroxyestr-4-ene);\n\t\t\t19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene);\n\t\t\t19-nor-5-androstenediol (3alpha,17beta-dihydroxyestr-5-ene);\n\t\t\t19-nor-4-androstenedione (estr-4-en-3,17-dione);\n\t\t\t19-nor-5-androstenedione (estr-5-en-3,17-dione);\n\t\t\tNorbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);\n\t\t\tNorclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);\n\t\t\tNorethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\tNormethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\tOxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);\n\t\t\tOxymesterone (Oxymestrone)(17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);\n\t\t\tOxymetholone (Anasterone)(17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-androstan-3-one);\n\t\t\tProstanozol (17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole);\n\t\t\tStanolone (4-Dihydrotestosterone)(Dihydrotestosterone)(17beta-hydroxy-androstan-3-one);\n\t\t\tStanozolol (Androstanazole)(17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-pyrazole);\n\t\t\tStenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);\n\t\t\tTestolactone (1-Dehydrotestololactone)(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);\n\t\t\tTestosterone (17beta-hydroxandrost-4-en-3-one);\n\t\t\tTetrahydrogestrinone (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);\n\t\t\tTrenbolone (Trienbolone)(Trienolone)(17beta-hydroxyestr-4,9,11-trien-3-one); and\n\t\t\tAny salt, ester, or ether of a drug or substance described or listed in this paragraph. However, such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the United States Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes any such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subsection.","type":"section","prefixes":["6"],"prefix":"6","entire_prefix":"6","prefix_anchor":"6","level":1,"prior_prefix":"5","next_prefix":"7"},"7":{"id":273845,"text":"Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration.","type":"section","prefixes":["7"],"prefix":"7","entire_prefix":"7","prefix_anchor":"7","level":1,"prior_prefix":"6"}},"ancestry":[{"id":13782,"edition_id":1,"name":"Standards and Schedules","identifier":"5","label":"article","depth":4,"order_by":1,"parent_id":13240,"metadata":{},"date_created":"2026-06-26 03:45:52","date_modified":"2026-06-26 03:45:52","permalink":{"id":243623,"object_type":"structure","relational_id":13782,"identifier":"5","token":"54.1\/III\/34\/5","url":"\/54.1\/III\/34\/5\/","edition_id":1,"permalink":0,"preferred":1}},{"id":13240,"edition_id":1,"name":"Drug Control Act","identifier":"34","label":"chapter","depth":3,"order_by":1,"parent_id":12758,"metadata":{},"date_created":"2026-06-26 03:44:30","date_modified":"2026-06-26 03:44:30","permalink":{"id":243223,"object_type":"structure","relational_id":13240,"identifier":"34","token":"54.1\/III\/34","url":"\/54.1\/III\/34\/","edition_id":1,"permalink":0,"preferred":1}},{"id":12758,"edition_id":1,"name":"Professions and Occupations Regulated by Boards Within the Department of Health Professions","identifier":"III","label":"subtitle","depth":2,"order_by":1,"parent_id":12754,"metadata":{},"date_created":"2026-06-26 03:43:51","date_modified":"2026-06-26 03:43:51","permalink":{"id":241105,"object_type":"structure","relational_id":12758,"identifier":"III","token":"54.1\/III","url":"\/54.1\/III\/","edition_id":1,"permalink":0,"preferred":1}},{"id":12754,"edition_id":1,"name":"Professions and Occupations","identifier":"54.1","label":"title","depth":1,"order_by":1,"parent_id":null,"metadata":{},"date_created":"2026-06-26 03:43:51","date_modified":"2026-06-26 03:43:51","permalink":{"id":239313,"object_type":"structure","relational_id":12754,"identifier":"54.1","token":"54.1","url":"\/54.1\/","edition_id":1,"permalink":0,"preferred":1}}],"structure_contents":[{"id":66818,"structure_id":13782,"section_number":"54.1-3443","catch_line":"Board to administer article","url":"\/54.1-3443\/","token":"54.1\/III\/34\/5\/54.1-3443","metadata":false},{"id":70506,"structure_id":13782,"section_number":"54.1-3444","catch_line":"Controlled substances included by whatever name designated","url":"\/54.1-3444\/","token":"54.1\/III\/34\/5\/54.1-3444","metadata":false},{"id":55398,"structure_id":13782,"section_number":"54.1-3445","catch_line":"Placement of substance in Schedule I","url":"\/54.1-3445\/","token":"54.1\/III\/34\/5\/54.1-3445","metadata":false},{"id":61892,"structure_id":13782,"section_number":"54.1-3446","catch_line":"Schedule I","url":"\/54.1-3446\/","token":"54.1\/III\/34\/5\/54.1-3446","metadata":false},{"id":65202,"structure_id":13782,"section_number":"54.1-3447","catch_line":"Placement of substance in Schedule II","url":"\/54.1-3447\/","token":"54.1\/III\/34\/5\/54.1-3447","metadata":false},{"id":56998,"structure_id":13782,"section_number":"54.1-3448","catch_line":"Schedule II","url":"\/54.1-3448\/","token":"54.1\/III\/34\/5\/54.1-3448","metadata":false},{"id":62478,"structure_id":13782,"section_number":"54.1-3449","catch_line":"Placement of substance in Schedule III","url":"\/54.1-3449\/","token":"54.1\/III\/34\/5\/54.1-3449","metadata":false},{"id":76280,"structure_id":13782,"section_number":"54.1-3450","catch_line":"Schedule III","url":"\/54.1-3450\/","token":"54.1\/III\/34\/5\/54.1-3450","metadata":false},{"id":56931,"structure_id":13782,"section_number":"54.1-3451","catch_line":"Placement of substance in Schedule IV","url":"\/54.1-3451\/","token":"54.1\/III\/34\/5\/54.1-3451","metadata":false},{"id":62803,"structure_id":13782,"section_number":"54.1-3452","catch_line":"Schedule IV","url":"\/54.1-3452\/","token":"54.1\/III\/34\/5\/54.1-3452","metadata":false},{"id":67045,"structure_id":13782,"section_number":"54.1-3453","catch_line":"Placement of substance in Schedule V","url":"\/54.1-3453\/","token":"54.1\/III\/34\/5\/54.1-3453","metadata":false},{"id":86457,"structure_id":13782,"section_number":"54.1-3454","catch_line":"Schedule V","url":"\/54.1-3454\/","token":"54.1\/III\/34\/5\/54.1-3454","metadata":false},{"id":82814,"structure_id":13782,"section_number":"54.1-3455","catch_line":"Schedule VI","url":"\/54.1-3455\/","token":"54.1\/III\/34\/5\/54.1-3455","metadata":false},{"id":87313,"structure_id":13782,"section_number":"54.1-3456","catch_line":"Controlled substance analog","url":"\/54.1-3456\/","token":"54.1\/III\/34\/5\/54.1-3456","metadata":false},{"id":54792,"structure_id":13782,"section_number":"54.1-3456.1","catch_line":"Drugs of concern","url":"\/54.1-3456.1\/","token":"54.1\/III\/34\/5\/54.1-3456.1","metadata":false}],"previous_section":{"id":62478,"structure_id":13782,"section_number":"54.1-3449","catch_line":"Placement of substance in Schedule III","url":"\/54.1-3449\/","token":"54.1\/III\/34\/5\/54.1-3449","metadata":false},"next_section":{"id":56931,"structure_id":13782,"section_number":"54.1-3451","catch_line":"Placement of substance in Schedule IV","url":"\/54.1-3451\/","token":"54.1\/III\/34\/5\/54.1-3451","metadata":false},"metadata":false,"official_url":"https:\/\/law.lis.virginia.gov\/vacode\/54.1-3450\/","history_text":"

This law was first created in 1972. The record of its establishment is cataloged in chapter 798 of that year\u2019s edition of \u201cActs of Assembly,\u201d the annual state publication listing all changes made to the Code of Virginia in that year. Unfortunately, the 1972 \u201cActs\u201d aren\u2019t available online. It has been modified 15 times. Those modifications are cataloged by \u201cThe Acts of Assembly,\u201d a state publication, by year and chapter. Those modifications that can be read on the General Assembly\u2019s website will be linked accordingly. Those modifications are as follows: in 1976, chapter 614; in 1977, chapter 302; in 1979, chapter 387; in 1982, chapter 505; in 1988, chapters 283 and 765; in 1992, chapter 737; in 2000, chapters 135<\/a> and 348<\/a>; in 2003, chapter 640<\/a>; in 2005, chapter 119<\/a>; in 2006, chapter 346<\/a>; in 2007, chapter 14<\/a>; in 2010, chapter 423<\/a>; in 2013, chapter 233<\/a>; in 2014, chapter 74<\/a>; in 2015, chapter 303<\/a>.<\/p>","references":[{"id":54127,"section_number":"54.1-3222","catch_line":"TPA certification; certification for treatment of diseases or abnormal conditions with therapeutic pharmaceutical agents (TPAs)","order_by":null,"url":"\/54.1-3222\/"},{"id":85347,"section_number":"54.1-3303","catch_line":"Prescriptions to be issued and drugs to be dispensed for medical or therapeutic purposes only","order_by":null,"url":"\/54.1-3303\/"}],"refers_to":false,"permalink":{"id":243653,"object_type":"law","relational_id":76280,"identifier":"54.1-3450","token":"54.1\/III\/34\/5\/54.1-3450","url":"\/54.1-3450\/","edition_id":1,"permalink":0,"preferred":1},"url":"\/54.1-3450\/","token":"54.1\/III\/34\/5\/54.1-3450","dublin_core":{"Title":"Schedule III","Type":"Text","Format":"text\/html","Identifier":"\u00a7 54.1-3450","Relation":"Code of Virginia"},"html":"\n\t\t\t\t\t\t

The controlled substances<\/span> listed in this section are included in Schedule III:<\/p><\/section>\n\t\t\t\t\t\t

1.<\/span> Unless specifically exempted or listed in another schedule, any material<\/span>, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:\n\t\t\tAny substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules<\/span>;\n\t\t\tAny compound, mixture or preparation containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and one or more other active medicinal ingredients which are not listed in Schedules<\/span> II through V;\n\t\t\tAny suppository dosage form containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and approved by the Food and Drug Administration for marketing only as a suppository;\n\t\t\tChlorhexadol;\n\t\t\tAny drug product<\/span> containing gamma hydroxybutyric acid, including its salts, isomers<\/span>, and salts of isomers<\/span>, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355);\n\t\t\tEmbutramide;\n\t\t\tKetamine, its salts, isomers<\/span>, and salts of isomers<\/span> (some other names: [+-] -2-[2-chlorophenyl]-2-[methylamino]-cyclohexanone);\n\t\t\tLysergic acid;\n\t\t\tLysergic acid amide;\n\t\t\tMethyprylon;\n\t\t\tPerampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benxonitrile], including its salts, isomers<\/span>, and salts of isomers<\/span>;\n\t\t\tSulfondiethylmethane;\n\t\t\tSulfonethylmethane;\n\t\t\tSulfonmethane; and\n\t\t\tTiletamine-zolazepam combination product or any salt thereof. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

2.<\/span> Nalorphine. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

3.<\/span> Unless specifically excepted or unless listed in another schedule:\n\t\t\ta. Any material<\/span>, compound, mixture, or preparation containing any of the following narcotic drugs<\/span> or their salts thereof:\n\t\t\tBuprenorphine.\n\t\t\tb. Any material<\/span>, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs<\/span>, or any salts thereof:\n\t\t\tNot more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;\n\t\t\tNot more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

4.<\/span> Unless specifically excepted or unless listed in another schedule, any material<\/span>, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers<\/span> (whether optical, position, or geometric), and salts of such isomers<\/span> whenever the existence of such salts, isomers<\/span>, and salts of isomers<\/span> is possible within the specific chemical designation:\n\t\t\tBenzphetamine;\n\t\t\tChlorphentermine;\n\t\t\tClortermine;\n\t\t\tPhendimetrazine. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

5.<\/span> The Board<\/span> may except by regulation any compound, mixture, or preparation containing any stimulation or depressant substance listed in subsection A from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

6.<\/span> Unless specifically excepted or unless listed in another schedule, any material<\/span>, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers<\/span>, and salts of isomers<\/span> whenever the existence of such salts of isomers<\/span> is possible within the specific chemical designation:\n\t\t\tAnabolic steroids<\/span>, including, but not limited to:\n\t\t\t3beta,17-dihydroxy-5a-androstane;\n\t\t\t3alpha,17beta-dihydroxy-5a-androstane;\n\t\t\t5alpha-androstan-3,17-dione;\n\t\t\t1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene);\n\t\t\t1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);\n\t\t\t4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);\n\t\t\t5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);\n\t\t\t1-androstenedione ([5alpha]-androst-1-en-3,17-dione);\n\t\t\t4-androstenedione (androst-4-en-3,17-dione);\n\t\t\t5-androstenedione (androst-5-en-3,17-dione);\n\t\t\tBolasterone (7alpha,17alpha-dimenthyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tBoldenone (Dehydrotestosterone)(17beta-hydroxyandrost-1,4,-diene-3-one);\n\t\t\tBoldione (androsta-1, 4-diene-3, 17-dione);\n\t\t\tCalusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tClostebol (4-Chlorotestosterone)(Chlorotestosterone)(4-chloro-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tDehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);\n\t\t\tDelta1-dihydrotestosterone (1-testosterone)(17beta-hydroxy-5alpha-androst-1-en-3-one);\n\t\t\tDesoxymethyltestosterone (madol)(17alpha-methyl-5alpha-androst-2-en-17beta-ol);\n\t\t\tDromostanolone (Drostanolone)(17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);\n\t\t\tEthylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);\n\t\t\tFluoxymesterone (9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one);\n\t\t\tFormyldienolone (Formebolone)(2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-di en-3-one);\n\t\t\tFurazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);\n\t\t\t13-beta-ethyl-17alpha-hydroxygon-4-en-3-one;\n\t\t\t4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);\n\t\t\t4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);\n\t\t\tMestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);\n\t\t\tMesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);\n\t\t\tMethandriol (methylandrostenediol)(17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);\n\t\t\tMethandrostenolone (Methandienone)(Dehydromethyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);\n\t\t\tMethasterone (2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one);\n\t\t\tMethenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);\n\t\t\t17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane;\n\t\t\t17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;\n\t\t\t17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene);\n\t\t\t17alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);\n\t\t\tMethyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);\n\t\t\tMethyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);\n\t\t\t17-Methyltestosterone (Methyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tMibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\t17alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)(17-alpha-methyl-1-testosterone);\n\t\t\tNandrolone (19-Nortestosterone)(17beta-hydroxyestr-4-en-3-one);\n\t\t\t19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);\n\t\t\t19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene);\n\t\t\t19-nor-4-androstenediol (3alpha,17beta-dihydroxyestr-4-ene);\n\t\t\t19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene);\n\t\t\t19-nor-5-androstenediol (3alpha,17beta-dihydroxyestr-5-ene);\n\t\t\t19-nor-4-androstenedione (estr-4-en-3,17-dione);\n\t\t\t19-nor-5-androstenedione (estr-5-en-3,17-dione);\n\t\t\tNorbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);\n\t\t\tNorclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);\n\t\t\tNorethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\tNormethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\tOxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);\n\t\t\tOxymesterone (Oxymestrone)(17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);\n\t\t\tOxymetholone (Anasterone)(17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-androstan-3-one);\n\t\t\tProstanozol (17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole);\n\t\t\tStanolone (4-Dihydrotestosterone)(Dihydrotestosterone)(17beta-hydroxy-androstan-3-one);\n\t\t\tStanozolol (Androstanazole)(17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-pyrazole);\n\t\t\tStenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);\n\t\t\tTestolactone (1-Dehydrotestololactone)(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);\n\t\t\tTestosterone (17beta-hydroxandrost-4-en-3-one);\n\t\t\tTetrahydrogestrinone (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);\n\t\t\tTrenbolone (Trienbolone)(Trienolone)(17beta-hydroxyestr-4,9,11-trien-3-one); and\n\t\t\tAny salt, ester, or ether of a drug or substance described or listed in this paragraph. However, such term does not include an anabolic steroid<\/span> which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the United States Secretary of Health and Human Services for such administration. If any person<\/span> prescribes, dispenses<\/span>, or distributes<\/span> any such steroid for human use, such person<\/span> shall be considered to have prescribed, dispensed, or distributed an anabolic steroid<\/span> within the meaning of this subsection. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

7.<\/span> Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product<\/span> approved by the U.S. Food and Drug Administration. <\/i><\/a><\/p><\/section>","plain_text":" CODE OF VIRGINIA\n\nSCHEDULE III (\u00a7 54.1-3450)\n\nThe controlled substances listed in this section are included in Schedule III:\n\n1. Unless specifically exempted or listed in another schedule, any material,\ncompound, mixture, or preparation which contains any quantity of the following\nsubstances having a depressant effect on the central nervous system:\n\t\t\tAny substance which contains any quantity of a derivative of barbituric acid,\nor any salt of a derivative of barbituric acid, except those substances which\nare specifically listed in other schedules;\n\t\t\tAny compound, mixture or preparation containing amobarbital, secobarbital, or\npentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and one\nor more other active medicinal ingredients which are not listed in Schedules II\nthrough V;\n\t\t\tAny suppository dosage form containing amobarbital, secobarbital, or\npentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and\napproved by the Food and Drug Administration for marketing only as a\nsuppository;\n\t\t\tChlorhexadol;\n\t\t\tAny drug product containing gamma hydroxybutyric acid, including its salts,\nisomers, and salts of isomers, for which an application is approved under\nsection 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355);\n\t\t\tEmbutramide;\n\t\t\tKetamine, its salts, isomers, and salts of isomers (some other names: [+-]\n-2-[2-chlorophenyl]-2-[methylamino]-cyclohexanone);\n\t\t\tLysergic acid;\n\t\t\tLysergic acid amide;\n\t\t\tMethyprylon;\n\t\t\tPerampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)\nbenxonitrile], including its salts, isomers, and salts of isomers;\n\t\t\tSulfondiethylmethane;\n\t\t\tSulfonethylmethane;\n\t\t\tSulfonmethane; and\n\t\t\tTiletamine-zolazepam combination product or any salt thereof.\n\n2. Nalorphine.\n\n3. Unless specifically excepted or unless listed in another schedule:\n\t\t\ta. Any material, compound, mixture, or preparation containing any of the\nfollowing narcotic drugs or their salts thereof:\n\t\t\tBuprenorphine.\n\t\t\tb. Any material, compound, mixture, or preparation containing limited\nquantities of any of the following narcotic drugs, or any salts thereof:\n\t\t\tNot more than 1.8 grams of codeine, or any of its salts, per 100 milliliters\nor not more than 90 milligrams per dosage unit, with an equal or greater\nquantity of an isoquinoline alkaloid of opium;\n\t\t\tNot more than 1.8 grams of codeine, or any of its salts, per 100 milliliters\nor not more than 90 milligrams per dosage unit, with one or more active,\nnonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 1.8 grams of dihydrocodeine, or any of its salts, per 100\nmilliliters or not more than 90 milligrams per dosage unit, with one or more\nactive, nonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 300 milligrams of ethylmorphine, or any of its salts, per 100\nmilliliters or not more than 15 milligrams per dosage unit, with one or more\ningredients in recognized therapeutic amounts;\n\t\t\tNot more than 500 milligrams of opium per 100 milliliters or per 100 grams,\nor not more than 25 milligrams per dosage unit, with one or more active,\nnonnarcotic ingredients in recognized therapeutic amounts;\n\t\t\tNot more than 50 milligrams of morphine, or any of its salts, per 100\nmilliliters or per 100 grams with one or more active, nonnarcotic ingredients in\nrecognized therapeutic amounts.\n\n4. Unless specifically excepted or unless listed in another schedule, any\nmaterial, compound, mixture, or preparation which contains any quantity of the\nfollowing substances having a stimulant effect on the central nervous system,\nincluding its salts, isomers (whether optical, position, or geometric), and\nsalts of such isomers whenever the existence of such salts, isomers, and salts\nof isomers is possible within the specific chemical designation:\n\t\t\tBenzphetamine;\n\t\t\tChlorphentermine;\n\t\t\tClortermine;\n\t\t\tPhendimetrazine.\n\n5. The Board may except by regulation any compound, mixture, or preparation\ncontaining any stimulation or depressant substance listed in subsection A from\nthe application of all or any part of this chapter if the compound, mixture, or\npreparation contains one or more active medicinal ingredients not having a\nstimulant or depressant effect on the central nervous system, and if the\nadmixtures are included therein in combinations, quantity, proportion, or\nconcentration that vitiate the potential for abuse of the substances which have\na stimulant or depressant effect on the central nervous system.\n\n6. Unless specifically excepted or unless listed in another schedule, any\nmaterial, compound, mixture, or preparation containing any quantity of the\nfollowing substances, including its salts, isomers, and salts of isomers\nwhenever the existence of such salts of isomers is possible within the specific\nchemical designation:\n\t\t\tAnabolic steroids, including, but not limited to:\n\t\t\t3beta,17-dihydroxy-5a-androstane;\n\t\t\t3alpha,17beta-dihydroxy-5a-androstane;\n\t\t\t5alpha-androstan-3,17-dione;\n\t\t\t1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene);\n\t\t\t1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);\n\t\t\t4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);\n\t\t\t5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);\n\t\t\t1-androstenedione ([5alpha]-androst-1-en-3,17-dione);\n\t\t\t4-androstenedione (androst-4-en-3,17-dione);\n\t\t\t5-androstenedione (androst-5-en-3,17-dione);\n\t\t\tBolasterone (7alpha,17alpha-dimenthyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tBoldenone (Dehydrotestosterone)(17beta-hydroxyandrost-1,4,-diene-3-one);\n\t\t\tBoldione (androsta-1, 4-diene-3, 17-dione);\n\t\t\tCalusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tClostebol\n(4-Chlorotestosterone)(Chlorotestosterone)(4-chloro-17beta-hydroxyandrost-4-en-3\n-one);\n\t\t\tDehydrochloromethyltestosterone\n(4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);\n\t\t\tDelta1-dihydrotestosterone\n(1-testosterone)(17beta-hydroxy-5alpha-androst-1-en-3-one);\n\t\t\tDesoxymethyltestosterone\n(madol)(17alpha-methyl-5alpha-androst-2-en-17beta-ol);\n\t\t\tDromostanolone\n(Drostanolone)(17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);\n\t\t\tEthylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);\n\t\t\tFluoxymesterone\n(9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one);\n\t\t\tFormyldienolone\n(Formebolone)(2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-di\nen-3-one);\n\t\t\tFurazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);\n\t\t\t13-beta-ethyl-17alpha-hydroxygon-4-en-3-one;\n\t\t\t4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);\n\t\t\t4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);\n\t\t\tMestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);\n\t\t\tMesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);\n\t\t\tMethandriol\n(methylandrostenediol)(17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);\n\t\t\tMethandrostenolone\n(Methandienone)(Dehydromethyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-\n1,4-dien-3-one);\n\t\t\tMethasterone (2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one);\n\t\t\tMethenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);\n\t\t\t17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane;\n\t\t\t17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;\n\t\t\t17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene);\n\t\t\t17alpha-methyl-4-hydroxynandrolone\n(17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);\n\t\t\tMethyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);\n\t\t\tMethyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);\n\t\t\t17-Methyltestosterone\n(Methyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);\n\t\t\tMibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\t17alpha-methyl-delta1-dihydrotestosterone\n(17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)(17-alpha-methyl-1-test\nosterone);\n\t\t\tNandrolone (19-Nortestosterone)(17beta-hydroxyestr-4-en-3-one);\n\t\t\t19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);\n\t\t\t19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene);\n\t\t\t19-nor-4-androstenediol (3alpha,17beta-dihydroxyestr-4-ene);\n\t\t\t19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene);\n\t\t\t19-nor-5-androstenediol (3alpha,17beta-dihydroxyestr-5-ene);\n\t\t\t19-nor-4-androstenedione (estr-4-en-3,17-dione);\n\t\t\t19-nor-5-androstenedione (estr-5-en-3,17-dione);\n\t\t\tNorbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);\n\t\t\tNorclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);\n\t\t\tNorethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\tNormethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);\n\t\t\tOxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);\n\t\t\tOxymesterone\n(Oxymestrone)(17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);\n\t\t\tOxymetholone\n(Anasterone)(17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-androstan\n-3-one);\n\t\t\tProstanozol (17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole);\n\t\t\tStanolone\n(4-Dihydrotestosterone)(Dihydrotestosterone)(17beta-hydroxy-androstan-3-one);\n\t\t\tStanozolol\n(Androstanazole)(17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-pyr\nazole);\n\t\t\tStenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);\n\t\t\tTestolactone\n(1-Dehydrotestololactone)(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic\nacid lactone);\n\t\t\tTestosterone (17beta-hydroxandrost-4-en-3-one);\n\t\t\tTetrahydrogestrinone\n(13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);\n\t\t\tTrenbolone (Trienbolone)(Trienolone)(17beta-hydroxyestr-4,9,11-trien-3-one);\nand\n\t\t\tAny salt, ester, or ether of a drug or substance described or listed in this\nparagraph. However, such term does not include an anabolic steroid which is\nexpressly intended for administration through implants to cattle or other\nnonhuman species and which has been approved by the United States Secretary of\nHealth and Human Services for such administration. If any person prescribes,\ndispenses, or distributes any such steroid for human use, such person shall be\nconsidered to have prescribed, dispensed, or distributed an anabolic steroid\nwithin the meaning of this subsection.\n\n7. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin\ncapsule in a drug product approved by the U.S. Food and Drug Administration.\n\nHISTORY: 1972, c. 798, \u00a7 54-524.84:8; 1976, c. 614; 1977, c. 302; 1979, c. 387;\n1982, c. 505; 1988, cc. 283, 765; 1992, c. 737; 2000, cc. 135, 348; 2003, c.\n640; 2005, c. 119; 2006, c. 346; 2007, c. 14; 2010, c. 423; 2013, c. 233; 2014,\nc. 74; 2015, c. 303.","edition":{"id":1,"name":"2025","slug":"2025","date_created":"2026-06-21 22:39:22","date_modified":"2026-06-21 22:39:22","current":1,"order_by":1,"last_import":null}}